Skip to main content
Genetics and Molecular Biology logoLink to Genetics and Molecular Biology
. 2016 Jan-Mar;39(1):14–23. doi: 10.1590/1678-4685-GMB-2015-0055

Genotypic diversity of the Killer Cell Immunoglobulin-like Receptors (KIR) and their HLA class I Ligands in a Saudi population

Suliman Y Al Omar 1, Afrah Alkuriji 1, Saleh Alwasel 1, javid Ahmed Dar 2, Alwaleed Alhammad 3, Stephen Christmas 4, Lamjed Mansour 1,5
PMCID: PMC4807387  PMID: 27007893

Abstract

Killer Cell Immunoglobulin-like Receptors (KIR) have been used as good markers for the study of genetic predisposition in many diseases and in human genetic population dynamics. In this context, we have investigated the genetic diversity of KIR genes and their main HLA class I ligands in Saudi population and compared the data with other studies of neighboring populations. One hundred and fourteen randomly selected healthy Saudi subjects were genotyped for the presence or absence of 16 KIR genes and their HLA-C1, -C2, -Bw4Thr80 and Bw4Ile80 groups, using a PCR-SSP technique. The results show the occurrence of the framework genes (3DL2, 3DL3 and 2DL4) and the pseudogenes (2DP1 and 3DP1) at highest frequencies. All inhibitory KIR (iKIR) genes appeared at higher frequencies than activating genes (aKIR), except for 2DS4 with a frequency of 90.35%. A total of 55 different genotypes were observed appearing at different frequencies, where 12 are considered novel. Two haplotypes were characterized, AA and Bx (BB and AB), which were observed in 24.5% and 75.5% respectively of the studied group. The frequencies of iKIR + HLA associations were found to be much higher than aKIR + HLA. KIR genes frequencies in the Saudi population are comparable with other Middle Eastern and North African populations.

Keywords: KIR diversity, gene polymorphism, molecular evolution, PCR SSP, population viability analysis

Introduction

Natural killer (NK) cells are considered the first line of defense of the innate immune response against both infected and malignantly transformed cells. They act through their cytotoxic activity or by the production of a panel of cytokines. These activities are accomplished by two subpopulations; CD56dim cells, mainly responsible for cytotoxic activity and CD56bright cells, having a role as cytokine producer cells (Caligiuri et al., 1989, Cooper et al., 2001). The killing activity of NK cells is regulated through a range of receptors belonging to different families. One common family of receptors are called killer cell immunoglobulin-like receptors (KIR) expressed by natural killer cells and a subset of T cells, are glycoproteins playing an important role in innate cytotoxic activity. Through their interactions with Human Leukocyte Antigens (HLA)-I and other ligands, they regulate the cytotoxic activity of the NK cells, by balancing the function of these cells between activating and inhibitory signals (Vilches and Parham, 2002, Parham, 2005, Parham and Moffett, 2013). The KIR genes form a cluster on chromosome 19q13.4 within the Leukocyte Receptor Complex (LRC) in a region spanning approximately 1 Mb (Wagtmann et al., 1997, Torkar et al., 1998). These KIR genes are characterized by their allelic and haplotypic polymorphisms which were associated with the resistancevs. susceptibility to many diseases, such as infections, cancers and autoimmunity (Kulkarni et al., 2008a, Al Omaret al., 2010, Houet al., 2010, Jiaoet al., 2010, Garcia-Leon et al., 2011, Augusto et al., 2012, Ivarsson et al., 2013, Jarduli et al., 2013, Chavan et al., 2014).

The KIR gene cluster is composed of 16 genes coding for activating or inhibitory receptors and two pseudogenes (Marsh et al., 2003a). KIR gene nomenclature as defined by the World Health Organization subcommittee was based on the structure of the encoded molecules. Thus according to the number of extracellular immunoglobulin domains (D) which may be double (2D) or triple (3D) and the length of the intracytoplasmic tail that would be long (L) or short (S), the KIR genes have been named and classified as inhibitory (with long cytoplasmic tail) or activating genes (having short cytoplasmic tail) (Long et al., 1996). Actually eight genes were reported coding inhibitory molecules named (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2 and KIR3DL3) and seven genes for the activating molecules (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5A/B and KIR3DS1). The gene KIR2DL4 appeared to have both functions (Faure and Long, 2002). KIR2DP1 and KIR3DP1 are pseudogenes (Wilson et al., 2000, Marsh et al., 2003b). Genetic variability in KIR between individuals results from allelic diversity for some genes and the composition of haplotypes (presence or absence of some genes) leading to different genotype composition. Currently, more than 500 different genotypes have been described (Gonzalez-Galarza et al., 2014). Four genes KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 considered as 'framework' are present in nearly all individuals, and for the other genotypes different combinations of genes lead to different haplotypes. Despite the number of the generated haplotypes, two distinct groups were defined, termed A and B, based upon gene content. Group B haplotypes were defined by the presence of at least one the following genes: KIR2DS1/2/3/5, KIR3DS1and KIR2DL5. Conversely, in group A haplotypes all these genes are missing (Uhrberg et al., 2002).

It is now accepted that the killing function of NK cells depends on the composition of activating and inhibitory receptors present on the membrane and the interaction with their HLA ligands. Specificity towards HLA-A, -B, -C and -G ligands has been demonstrated for some KIR molecules (Brookset al., 2000, Moretta et al., 2014). For HLA-C, based on the amino acid at position 80 in the heavy chain, two groups of ligands were reported. In the HLA-C1 group, position 80 is occupied by the amino acid lysine, while in the HLA-C2 group the amino acid at the same position is asparagine (Moretta et al., 1995). The discrimination between the two groups of HLA-C is allowed by position 44 in the D1 domain of KIR. The inhibitory KIR2DL2/3 and the activating KIR2DS2 bind to the HLA-C1 ligand while KIR2DL1 and KIR2DS1 bind to HLA-C2 (Du et al., 2007). The inhibitory signal triggered by the KIR2DL2/3 + HLA-C1 interaction is relatively weaker as compared with that triggered by the KIR2DL1 + HLA-C2 interaction (Mandelboim et al., 1996, Moesta et al., 2008). The ligand of the receptors KIR3DL1/S1 is the HLA-B allotypes and certain HLA-A molecules that express the Bw4 epitope, serologically defined having a determined motif at amino acid position 77-83 (Cella et al., 1994, Gumperz et al., 1995). According to the amino acid at position 80 of HLA-B having the Bw4 epitope, a dimorphic molecule is expressed; Bw4 Isoleucine and Bw4 Threonine, which affects the strength of interaction with the KIR3DL1 receptor. The inhibitory signal triggered with HLA-B Bw4Ile80 is generally stronger than the one triggered with HLA-B Bw4 r80 (Gumperz et al., 1997, Carr et al., 2005). Other KIR-HLA interactions were reported for KIR3DL2 which binds HLA-A3 and HLA-A11, while the association KIR2DL4 -HLA-G remains controversial (Long and Rajagopalan, 2000,Hansasuta et al., 2004,Rajagopalan and Long, 2005, O'Connor et al., 2007).

The activating receptor KIR2DS1 has been shown to bind weakly to HLA-C2 whileKIR2DS2 binds weakly to HLA-C1 (Stewart et al., 2005, Chewning et al., 2007, Foley et al., 2008).

The aim of this work is to contribute to the assessment of the pattern of genetic diversity in 114 healthy Saudi subjects based on the genetic polymorphism of the KIR genes. Our results were used for comparative analysis with other published data for Saudis and neighboring populations. Moreover, the main HLA class I ligands were also typed in order to evaluate the killing function efficiency of the NK cells.

Materials and Methods

Study group

Blood samples were obtained from 114 unrelated healthy individuals selected randomly from the Saudi population visiting the King Khaled University Hospital (KKUH), Riyadh, Kingdom of Saudi Arabia. All participants were asked for their consent according to the permit issued by the Ethics Committee of King Saud University for this study. Among this healthy group, 65 were women and 49 men. Genomic DNA was prepared using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA).

KIR and HLA ligands genotyping

KIR genotyping was performed by PCR-SSP for the presence or absence of the 14 KIR genes, (KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1) and the two pseudogenes(3DP1 and 2DP1). Genotyping was firstly performed by the commercially KIR typing kit (Miltenyi Biotec, Inc, Germany) according to the manufacturer's recommendations and the results were confirmed by an alternative protocol using a set of primers previously reported by Vilches et al (2007).

For HLA-C1, HLA-C2 and HLA-B Bw4 group typing, the same primers reported by Tajik et al (2010) were used. For each assay, PCR was performed in a 20 μL final volume containing 4 μL of 5x FIREPol® Master Mix ready-to-use (Solis Biodyne, Estonia), 0.2 pmol of each primer, 50-100 ng of DNA and ultra-pure water (MilliQ). In addition, for each amplification reaction an internal control of the growth hormone gene was amplified using the primers hGH forward (5'-GCCTTCCCAACCATTCCCT TA-3') and hGH reverse, (5'-GTCCATGTCCTTCCTGA AGCA-3') (Tajiket al., 2009, 2010). The PCR cycling protocol used consisted of an initial step of denaturation at 94°C followed by 5 cycles of 20 s at 94°C, 30 s at 64°C and 60 s at 72°C, 25 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 90 s; 5 cycles of 94C° for 30 s, 55°C for 30 min, and 72°C for 90s, followed by a final extension step for 10 min at 72°C. All PCR assays were performed with the Techne TC-Plus Satellites (Bibby Scientific, Staffordshire, UK) thermocycler apparatus.

The PCR products were analyzed by electrophoresis in 2% agarose gel stained with ethidium bromide and visualized on an UV transilluminator using a gel documentation system (Gel225 DocXR BioRad) to check the presence or absence of gene-specific amplicons.

Statistical analysis

The frequencies of the KIR genes and KIR AA and BX genotypes, as well as their ligands HLA-C1 and -C2 groups and HLA-B Bw4 were established by direct counting. The significance of differences of KIR gene proportions between our sampled populations and other selected ones were estimated using the two-tailed Fisher's exact test with SigmaPlot software version 11. P values of < 0.05 were considered to confirm significance of differences. All values in the studied groups were in Hardy–Weinberg equilibrium. Principal component analysis (PCA) and estimation of the Euclidean distances were performed with Primer E-6 Package(Clarke, 1993) to minimize the genetic distances between our population and other selected ones.

Results and Discussion

The aim of this work was to assess the KIR gene diversity in a Saudi group of 114 randomly selected healthy unrelated individuals. For this purpose, we used two protocols based on the Sequence-Specific Primer–directed Polymerase Chain Reaction (SSP-PCR). All samples were typed with a commercially KIR typing kit (Miltenyi Biotec, Inc) using unknown primers and a protocol based on the primers designed byVilches et al. (2007). Both protocols gave 100% concordant results. The distribution frequencies of the 16KIR genes and their HLA class I ligands in a randomly selected 114 healthy unrelated Saudi group are reported in Figure 1.

Figure 1. Distribution of observed frequencies of KIR genes and their HLA ligands among the studied Saudi population. Blue = inhibitory, grey = activating, black = pseudogenes, hatched = HLA ligands.

Figure 1

The framework genes KIR3DL2, -DL3 and -3DP1 appeared in 99.1% (113/114) of the subjects. The framework gene 2DL4 was observed in 97.4% (111/144). The inhibitory genes 2DL1, 2DL3, 3DL1 appeared with relatively high frequencies (> 80%) and only 2DL2 and 2DL5 were observed with the same frequency at 58.8%. The second pseudogene 2DP1 had the same frequency as 3DP1.

Comparisons of these frequencies with those of 12 other studied populations including two Saudi groups were made (Tables 1 and2). We noticed that while the percentages of the framework genes did not reach 100%, they are in the range of all reported studies (P < 0.05). For both studied Saudi groups, these percentages were 100% for all framework genes (Gaafar et al., 2011, Osman et al., 2014). For these genes, only the percentages in a group from Southern Turkey reported by Ozturk et al. (2012) are less than 100%. These framework genes were lacking in three individuals. Two individuals were A haplotypes and lacking two framework genes simultaneously (3 DL3, 2DL4 and 3DL2, 2DL4). These individuals would be homozygote for the Kir haplotypes and could carry a large deletion spanning these loci, probably as a consequence of unequal crossing over events. However, errors caused by limitations in the techniques cannot be excluded. Sequencing of these unusual two individuals should confirm this information. Double deletion of the framework genes were also reported in other studies, such as of the admixed population of Belem, in the Northern region of Brazil and in a Swedish study group (Martin et al., 2008,Pedroza et al., 2011,Gonzalez-Galarza et al.,2014).

Table 1. Comparative analysis of the distribution of KIR genes between different related populations used for comparisons with our studied Saudi population group (Sap3).

A. Observed percentages of KIRs genes reported in different studied groups.
KIR genes Sap3 Sap2 Sap1 Pal Leb Oma Ira-Ar Ira Tun Mor-Ch Sen Turk Ind
(n=114) (n=148) (n=162) (n=105) (n=120) (n = 99) (n = 76) (n = 200) (n=114) (n = 67) (n= 118) (n = 200) (n = 139)
Inhibitory genes 3DL2 99.12 100 100 100 100 100 100 100 100 100 100 99.5 100
3DL3 99.12 100 100 100 100 100 100 100 NR 97 NR 99.5 100
2DL4 97.37 100 100 100 100 100 100 100 100 100 100 99 100
2DL1 88.6 98 96.3 83 99.2 98 100 96.5 99.1 95.5 100 97 97.8
2DL3 82.46 83.1 91.4 85 88.3 87.9 89.5 86.5 91.2 73.1 100 80 85.8
3DL1 92.98 94.4 95.7 88 95.8 96 85.5 91.5 100 100 99 91 91.4
2DL2 58.77 68.2 56.2 62 59.2 50.5 63.1 56.5 59.6 70.1 55 53 62
2DL5 58.77 64.9 56.2 63 58.3 59.6 67.1 61.5 60.5 67.2 52 58 71.7
Activating genes 2DS1 30.7 43.9 33.3 44 40.8 32.3 42.7 45.5 22.8 25.4 13 38 47.8
2DS2 56.14 73 57.4 64 59.2 49.5 56.3 57.5 59.6 65.7 42 53 62.3
2DS3 44.74 43.2 38.3 37 37.5 30.3 50 38 38.6 52.2 24 33 44.2
2DS4 90.35 92.5 93.8 88 95 94.9 98.7 91.5 96.5 100 100 92 90.7
2DS5 28.95 43.9 27.8 27 30.8 39.4 35.5 40 23.7 32.8 30 39 46.4
3DS1 21.05 35.8 34.6 39 35.8 29.3 42.1 44.5 23.7 26.9 4 42 37
pseudogenes 2DP1 99.12 98 86 NR NR 98 98.7 96.5 NR 100 NR 96 97.8
3DP1 99.12 100 100 NR NR 100 100 100 100 100 100 99 NR
References Present work (Gaafar et al., 2011) (Osman et al., 2014) (Norman et al., 2001) (Rayes et al., 2008) (Williams et al., 2004) (Norman et al., 2001) (Hiby et al., 2010) Unpublished (Hollenbachet al., 2010) (Denis et al., 2005) (Ozturk et al., 2012) (Kulkarni et al., 2008b)
B. Statistical significance of the distribution of frequency of KIR genes of Sap3 vs.related populations. Values in Bold indicate the significance of difference (p < 0.05).
KIR genes Sap2 Sap1 Pal Leb Oma Ira-Ar Ira Tun Mor-Ch Sen Turk Ind
Inhibitory genes 3DL2 0.91 0.88 0.95 0.99 0.92 0.82 0.77 0.98 0.77 0.99 0.71 0.94
3DL3 0.91 0.88 0.95 0.99 0.92 0.82 0.77 0.98 0.61 0.99 0.71 0.94
2DL4 0.17 0.15 0.29 0.24 0.31 0.42 0.09 0.26 0.48 0.25 0.55 0.19
2DL1 0.003 0.025 0.34 0.001 0.0013 0.005 0.012 0.002 0.19 Inf 0.001 0.002 0.004
2DL3 1 0.038 0.76 0.26 0.34 0.25 0.42 0.072 1.18 Inf 0.001 0.71 0.59
3DL1 0.84 0.53 0.22 0.56 0.57 0.13 0.80 0.014 0.073 0.043 0.61 0.73
2DL2 0.14 0.75 0.74 0.94 0.27 0.65 0.78 099 0.17 0.65 0.37 0.7
2DL5 0.42 0.68 0.69 0.98 0.92 0.35 072 0.96 0.33 0.29 0.95 0.046
Activating genus 2DS1 0.044 0.79 0.068 0.15 0.96 0.16 0.014 0.2 0.51 0.001 0.26 0.015
2DS2 0.007 0.95 0.31 0.75 0.38 0.91 0.9 0.7 0.27 0.044 0.65 0.37
2DS3 0.93 0.35 0.32 0.33 0.044 0.55 0.29 0.43 0.41 0.001 0.052 0.98
2DS4 0.75 0.46 0.58 0.30 0.35 0.052 0.89 0.13 0.02 0.002 0.86 0.85
2DS5 0.014 0.99 0.86 0.81 0.12 0.39 0.066 0.48 0.66 0.97 0.001 0.32
3DS1 0.012 0.019 0.005 0.017 0.21 0.003 Inf 0.001 0.74 0.47 0.0001 0.0001 0.009
Pseudogenes 2DP1 0.77 0.0001 NR NR 0.87 0.98 0.29 NR 0.77 0.99 0.87 0.86
3DP1 0.91 0.88 NR NR 0.92 0.82 0.77 0.98 0.77 0.99 0.65 NR

Sap1 and Sap2 are two studied groups of Saudi population; Pal, Palestinian; Leb, Lebanese; Oma, Omani; Ira-Ar, Iranians-Arab; Ira, Iranians; Tun, Tunisians; Mor-Ch, Moroccans Chaouya; Sen, Senegalese; Turk, Southern Turkey; Ind, Indians

Table 2. Statistical comparisons of AA /Bx genotypes between our population SaP3 and some related populations. Values in bold for p < 0.05.

Populations Sap3 Sap2 Sap1 Pal Leb Oma Ira-Ar Ira Tun Mor-Ch Sen Turk Ind
Genotypes AA 24.5 18.2 26.5 22.9 26.7 29.3 15.7 27.5 29.8 16.4 53 29 23.7
% Bx 75.5 81.8 72.9 77.1 73.3 70.7 83.3 72.5 70.2 83.5 47 71 76
p AA/Bx 0.28 0.76 0.91 0.80 0.51 0.23 0.33 0.43 0.28 < 0.001 0.44 0.98

The frequency of 2DL1 here reported is significantly different to almost all studied populations except the Palestinians and the Moroccan Chaouya groups. The highest frequency (100%) of this gene occurs in Senegalese, Iranian-Arab and Indian groups. Thus, only the Palestinian and the Moroccan Chaouya groups have no significant differences in the distribution of frequencies of inhibitory genes. Our Saudi group has only one significant difference in the frequencies ofiKIR genes with Saudi S2 group, Lebanese, Omani, Iranian-Arab, and Turkish groups and two significant differences with Saudi S1, Tunisian, Iranian and Indian groups. The most divergent was the Senegalese population with three significant differences in 2DL1, 2DL3 and 3DL1genes.

For the activating genes only the Tunisian group showed no significant differences in the frequencies of aKIRs with our studied group. One significant difference was observed with Saudi S1, Palestinians, Lebanese, Omani, Iranians-Arab, Iranian and Moroccan Chaouya. The Saudi S2 has four significant differences with our group. The Senegalese group remains the most divergent with five significant differences. And finally, in the distribution of the pseudo-genes, only the2DP1 in Saudi S1 appears lower than all the reported populations.

Based on the presence or absence of inhibitory and activating KIRgene content, two major haplotype groups A and B were considered. The homozygote AA haplotype is defined by the absence of all the following genes, KIR2DL2, −2DL5, −2DS1, −2DS2, −2DS3-2DS5 and -3DS1. Conversely, individuals carrying at least one of these genes are considered Bx genotype grouping AB and BB haplotypes.

Identification of KIR genes among the studied Saudi group showed the occurrence of 55 different genotypes (Figure 2). These genotypes were characterized by referring to the allele frequencies database (http://www.allelefrequencies.net) (Gonzalez-Galarza et al., 2014). Among the 55 genotypes identified 12 of them were new. Thirteen genotypes have frequencies > 1% and they represent 63% of the studied groups. The homozygote AA referenced as haplotype number 1 is the most frequent with 21.1%. This is the case for the two last reported Saudi groups (Sap1 and Sap2) and most other studied populations. Comparison made with the twelve selected groups, showed a significant difference in the frequency of haplotypes AA and BB only with the Senegalese study group (p < 0.001) (Table 2). In this African population we noted a frequency of the AA haplotype higher than Bx (42% vs. 38%). We noted the presence of the reference genotype number 6 with only 2.6%, which was reported at 8.8% in Sap1 and 8.7% in Sap2. The number of genotypes in common with Sap1 and Sap2 were 11 and 12 respectively. We recall that in these two Saudi groups 41 genotypes were reported in the Sap1 and 31 genotypes in the Sap2. Only five genotypes were common to the three subpopulations which are the references 1, 4, 6, 70 and 112. Thus, for a total of 127 genotypes observed in these Saudi groups, only 23 were observed in at least two groups, the remaining 104 genotypes were reported individually. This data suggest a high heterogeneity and diversity in the Saudi population.

Figure 2. Characterization and distribution of KIR genotypes observed in 114 Saudis individuals. Presence and absence of genes are indicated by filled and open rectangles, respectively.

Figure 2

Knowing the importance of some HLA ligands in the interactions with the KIR receptors, we have also studied the distribution of the frequencies of HLA-C1 and C2 and HLA Bw4 in this Saudi group (Figure 1). HLA-C1 and -C2 groups appeared with similar frequencies (72.8 and 71.05% respectively). HLA-B Bw4 occurred in 73.7% of the subjects. The groups HLA-B Bw4Thr80 and HLA-Bw4Ile80 were observed in 57.9% and 41.2% respectively of the typed individuals.

Table 3 shows the different genotypes of HLA KIR ligands observed in the study population. Six genotypes were observed. The most frequent was Bw4 + C1 + C2 carried by 29.8% individuals. Those carrying two different ligands were more frequent than those with only one ligand (Table 3). These results corroborate with those reported in the Iranian population (Tajik et al., 2010).

Table 3. Different associations of HLA KIR ligands among the studied Saudi population.

Ligands C1 C2 B Bw4 number %
C1/C2/B Bw4 + + + 34 29.82
C1/C2 + + 15 14.03
C1/B Bw4 + + 27 23.68
C2/B Bw4 + + 23 20.17
C1 + 6 5.26
C2 + 8 7.01

Analysis of different combinations between KIR genes and their supposed HLA ligands are presented in Table 4. We note that for the iKIR, the frequency of the individual sharing2DL2/3-C1 appeared with the highest frequency.2DL1-C2 and 3DL1-Bw4 were relatively high and had the same percentage. Conversely, the distribution of aKIR-HLA ligand is variable (Table 4). For the HLA-C1 ligand, it was observed associated with 2DL2/3 in 73.68% of the subjects against 42.09% for the 2DS2. The genotype 2DL2/3, 2DS2, C1 was observed in 28.9%. The percentage of2DL2/3 positive individuals without C1 was 27.27%vs. 13.15% for 2DS2.

Table 4. Distribution of iKIR and aKIR and their HLA ligands.

KIR + HLA % of individuals
iKIR + HLA 2DL2/3 + C1 73.68
2DL1 + C2 66.67
3DL1+ Bw4 66.67
3DL1 +B Bw4 Ile80 37.71
3DL1 +B Bw4 Thr80 50.87
aKIR + HLA 2DS2 + C1 42.09
2DS1 + C2 20.17
3DS1 + Bw4 19.2
3DS1 +B Bw4 Ile80 8.8
3DS1 +B Bw4 Thr80 17.5

The ligand HLA-C2 had a frequency of 71%. Its association withKIR2DL1 gave a stronger signal than the association2DL2/3-C1. The association 2DL1-C2 was observed with a frequency of 66.67% vs. 20.17% for the association of this ligand with the activating KIR 2DS1. The genotype2DL1-2DS1 was observed in 24.7% of individuals. Their simultaneous association with C2 ligand was observed in 18.4% cases only. 21.9% of the 2DL1+ and 34.3% of the 2DS1+ groups were C2 free.

HLA-B Bw4 occurred in 73.68% of the study group. 66.6% are 3DL1-Bw4+vs. 19.2.3% for the genotype 3DS1-Bw4. The genotype 3DL1, 3DS1, Bw4 was observed in 16.6% of cases. We have observed 27.3% of 3DL1 and 4.6% of 3DS1individuals without the B Bw4 ligand.

A principal component analysis mapping of the 12 selected populations based on the frequencies of 12 KIR genes is represented in Figure 3. The results show that our Saudi population Sap3 clusters well with other Asiatic and North African populations. The Senegalese population appears quite divergent and is located away from all other groups. It is worth mentioning that Sap3 is genetically closely related to the Tunisian population. The Sap1 group occurs in a same cluster with the Turkish, Lebanese and Omani population. However, the Iranians-Arab population shows some genetic distance from the Sap2 sample.

Figure 3. Spatial distribution along the first and second principal components (PC1 and PC2) grouping 74.2 of the variance of 12 KIR genes frequencies from our studied Saudi population (Sap3) and 11 other previously described populations). The relative contribution of each KIR gene to variability is represented by blue arrows. Circles indicate two different clusters obtained for two Euclidean distances (21 for the circle in blue and 42 for the circle in green). For an Euclidean distance 42, only the Senegalese population is out of the cluster.

Figure 3

These results corroborate with other paleoanthropic and genetic studies showing the common origin of the Saudis and other population belonging either to the Arabian Peninsula, Levant, African populations and other Asiatic ethnics groups (Abu-Amero et al., 2007, Abu-Amero et al., 2008, Cadenas et al., 2008, Abu-Amero et al., 2009, Abu-Amero et al., 2011, Rosa and Brehem, 2011, Soares et al., 2012, Abu-Amero et al., 2013, Alsmadi et al., 2013). In fact, according to the 'out of Africa theory' model, Saudi Arabia is thought to have played a key role in the dispersion of early human populations outside of Africa, mainly through the Sinai Peninsula and Bab-el-Mandeb routes probably since the last glacial period. Later, these people continued to spread to the Near East through the Levantine corridor (Petraglia, 2003, Alsmadi et al., 2013).

Through the KIR data analysis we confirmed that the Saudi Arabia population has mainly been a recipient of gene flow from the surrounding areas in Asia and Africa. Explorations KIR diversity of other admixed and unique populations of the Arabian Peninsula is very interesting and can provide more information about the evolutionary history and the dynamic of this ethnic group.

Acknowledgments

This project was supported by the NSTIP strategic technologies program (number 11MED1900-02) of the Kingdom of Saudi Arabia.

Footnotes

Associate Editor: Mara H. Hutz

References

  1. Abu-Amero KK, Cabrera VM, Larruga JM, Osman EA, Gonzalez AM, Al-Obeidan SA. Eurasian and Sub-Saharan African mitochondrial DNA haplogroup influences pseudo-exfoliation glaucoma development in Saudi patients. Mol Vis. 2011;17:543–547. [PMC free article] [PubMed] [Google Scholar]
  2. Abu-Amero KK, Gonzalez AM, Larruga JM, Bosley TM, Cabrera VM. Eurasian and African mitochondrial DNA influences in the Saudi Arabian population. BMC Evol Biol. 2007;7:32–32. doi: 10.1186/1471-2148-7-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Abu-Amero KK, Hellani A, Gonzalez AM, Larruga JM, Cabrera VM, Underhill PA. Saudi Arabian Y-Chromosome diversity and its relationship with nearby regions. BMC Genet. 2009;10:59–59. doi: 10.1186/1471-2156-10-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Abu-Amero KK, Jaeger M, Plantinga T, Netea MG, Hassan HY. Genetic Variation of TLR2 and TLR4 Among the Saudi Arabian Population: Insight into the Evolutionary Dynamics of the Arabian Peninsula. Genetic Testing and Molecular Biomarkers. 2013;17:166–169. doi: 10.1089/gtmb.2012.0281. [DOI] [PubMed] [Google Scholar]
  5. Abu-Amero KK, Larruga JM, Cabrera VM, Gonzalez AM. Mitochondrial DNA structure in the Arabian Peninsula. BMC Evol Biol. 2008;8:45–45. doi: 10.1186/1471-2148-8-45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol. 2010;71:976–981. doi: 10.1016/j.humimm.2010.06.019. [DOI] [PubMed] [Google Scholar]
  7. Alsmadi O, Thareja G, Alkayal F, Rajagopalan R, John SE, Hebbar P, Behbehani K, Thanaraj TA. Genetic Substructure of Kuwaiti Population Reveals Migration History. Plos One. 2013;8: doi: 10.1371/journal.pone.0074913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Augusto DG, Lobo-Alves SC, Melo MF, Pereira NF, Petzl-Erler ML. Activating KIR and HLA Bw4 ligands are associated to decreased susceptibility to pemphigus foliaceus, an autoimmune blistering skin disease. PLoS One. 2012;7: doi: 10.1371/journal.pone.0039991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brooks AG, Boyington JC, Sun PD. Natural killer cell recognition of HLA class I molecules. Rev Immunogenet. 2000;2:433–448. [PubMed] [Google Scholar]
  10. Cadenas AM, Zhivotovsky LA, Cavalli-Sforza LL, Underhill PA, Herrera RJ. Y-chromosome diversity characterizes the Gulf of Oman. Eur J Hum Genet. 2008;16:374–386. doi: 10.1038/sj.ejhg.5201934. [DOI] [PubMed] [Google Scholar]
  11. Caligiuri MA, Murray C, Levine H, Longtine JA, Ritz J. Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. Eur J Immunol. 1989;19:1735–1739. doi: 10.1002/eji.1830190931. [DOI] [PubMed] [Google Scholar]
  12. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005;175:5222–5229. doi: 10.4049/jimmunol.175.8.5222. [DOI] [PubMed] [Google Scholar]
  13. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994;180:1235–1242. doi: 10.1084/jem.180.4.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chavan VR, Chaudhari D, Ahir S, Ansari Z, Mehta P, Mania-Pramanik J. Variations in KIR genes: a study in HIV-1 serodiscordant couples. Biomed Res Int. 2014;2014:891402–891402. doi: 10.1155/2014/891402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179:854–868. doi: 10.4049/jimmunol.179.2.854. [DOI] [PubMed] [Google Scholar]
  16. Clarke KR. Nonparametric Multivariate Analyses of Changes in Community Structure. Australian Journal of Ecology. 1993;18:117–143. [Google Scholar]
  17. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97:3146–3151. doi: 10.1182/blood.v97.10.3146. [DOI] [PubMed] [Google Scholar]
  18. Denis L, Sivula J, Gourraud PA, Kerdudou N, Chout R, Ricard C, Moisan JP, Gagne K, Partanen J, Bignon JD. Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens. 2005;66:267–276. doi: 10.1111/j.1399-0039.2005.00473.x. [DOI] [PubMed] [Google Scholar]
  19. Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007;59:1–15. doi: 10.1007/s00251-006-0168-4. [DOI] [PubMed] [Google Scholar]
  20. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol. 2002;168:6208–6214. doi: 10.4049/jimmunol.168.12.6208. [DOI] [PubMed] [Google Scholar]
  21. Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol. 2008;20:555–563. doi: 10.1093/intimm/dxn013. [DOI] [PubMed] [Google Scholar]
  22. Gaafar A, Sheereen A, Iqneibi A, Mohamed G, Al Sulaiman A, Turpeinen H, Al Hussein K. Killer cell immuno-globulin-like receptor gene diversity in the Saudi population. Mol Biol Rep. 2011;38:2603–2610. doi: 10.1007/s11033-010-0401-y. [DOI] [PubMed] [Google Scholar]
  23. Garcia-Leon JA, Pinto-Medel MJ, Garcia-Trujillo L, Lopez-Gomez C, Oliver-Martos B, Prat-Arrojo I, Marin-Banasco C, Suardiaz-Garcia M, Maldonado-Sanchez R, Fernandez-Fernandez O, Leyva-Fernandez L. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol. 2011;48:1896–1902. doi: 10.1016/j.molimm.2011.05.018. [DOI] [PubMed] [Google Scholar]
  24. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, Silva AL, Ghattaoraya GS, Alfirevic A, Jones AR, Middleton D. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2014;43:D784–D788. doi: 10.1093/nar/gku1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier LL, Parham P. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 1997;158:5237–5241. [PubMed] [Google Scholar]
  26. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181:1133–1144. doi: 10.1084/jem.181.3.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, Rowland-Jones S, Braud VM. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is pep-tide-specific. Eur J Immunol. 2004;34:1673–1679. doi: 10.1002/eji.200425089. [DOI] [PubMed] [Google Scholar]
  28. Hiby SE, Ashrafian-Bonab M, Farrell L, Single RM, Balloux F, Carrington M, Moffett A, Ebrahimi Z. Distribution of killer cell immunoglobulin-like receptors (KIR) and their HLA-C ligands in two Iranian populations. Immuno-genetics. 2010;62:65–73. doi: 10.1007/s00251-009-0408-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hollenbach JA, Meenagh A, Sleator C, Alaez C, Bengoche M, Canossi A, Contreras G, Creary L, Evseeva I, Gorodezky C, Hardie RA, Karlsen TH, Lie B, Luo M, Martinetti M, Navarette C, de Oliveira DC, Ozzella G, Pasi A, Pavlova E, Pinto S, Porto LC, Santos P, Slavcev A, Srinak D, Tavoularis S, Tonks S, Trachtenberg E, Vejbaesya S, Middleton D. Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA. Tissue Antigens. 2010;76:9–17. doi: 10.1111/j.1399-0039.2010.01459.x. [DOI] [PubMed] [Google Scholar]
  30. Hou YF, Zhang YC, Jiao YL, Wang LC, Li JF, Pan ZL, Yang QR, Sun HS, Zhao YR. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus. 2010;19:20–26. doi: 10.1177/0961203309345779. [DOI] [PubMed] [Google Scholar]
  31. Ivarsson MA, Loh L, Marquardt N, Kekalainen E, Berglin L, Bjorkstrom NK, Westgren M, Nixon DF, Michaelsson J. Differentiation and functional regulation of human fetal NK cells. J Clin Invest. 2013;123:3889–3901. doi: 10.1172/JCI68989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jarduli LR, Sell AM, Reis PG, Sippert EA, Ayo CM, Mazini PS, Alves HV, Teixeira JJ, Visentainer JE. Role of HLA, KIR, MICA, and cytokines genes in leprosy. Biomed Res Int. 2013;2013:989837–989837. doi: 10.1155/2013/989837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Jiao YL, Zhang BC, You L, Li JF, Zhang J, Ma CY, Cui B, Wang LC, Chen ZJ, Zhao YR. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol. 2010;30:840–844. doi: 10.1007/s10875-010-9444-z. [DOI] [PubMed] [Google Scholar]
  34. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008a;20:343–352. doi: 10.1016/j.smim.2008.06.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kulkarni S, Single RM, Martin MP, Rajalingam R, Badwe R, Joshi N, Carrington M. Comparison of the rapidly evolving KIR locus in Parsis and natives of India. Immunogenetics. 2008b;60:121–129. doi: 10.1007/s00251-008-0279-1. [DOI] [PubMed] [Google Scholar]
  36. Long EO, Colonna M, Lanier LL. Inhibitory MHC class I receptors on NK and T cells: a standard nomenclature. Immunol Today. 1996;17:100–100. doi: 10.1016/0167-5699(96)80590-1. [DOI] [PubMed] [Google Scholar]
  37. Long EO, Rajagopalan S. HLA class I recognition by killer cell Ig-like receptors. Semin Immunol. 2000;12:101–108. doi: 10.1006/smim.2000.0212. [DOI] [PubMed] [Google Scholar]
  38. Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med. 1996;184:913–922. doi: 10.1084/jem.184.3.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Hum Immunol. 2003a;64:648–654. doi: 10.1016/s0198-8859(03)00067-3. [DOI] [PubMed] [Google Scholar]
  40. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens. 2003b;62:79–86. doi: 10.1034/j.1399-0039.2003.00072.x. [DOI] [PubMed] [Google Scholar]
  41. Martin MP, Single RM, Wilson MJ, Trowsdale J, Carrington M. KIR haplotypes defined by segregation analysis in 59 Centre d'Etude Polymorphisme Humain (CEPH) families. Immunogenetics. 2008;60:767–774. doi: 10.1007/s00251-008-0334-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180:3969–3979. doi: 10.4049/jimmunol.180.6.3969. [DOI] [PubMed] [Google Scholar]
  43. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med. 1995;182:875–884. doi: 10.1084/jem.182.3.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, Locatelli F, Mingari MC. Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol. 2014;164:253–264. doi: 10.1159/000365632. [DOI] [PubMed] [Google Scholar]
  45. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics. 2001;52:195–205. doi: 10.1007/s002510000281. [DOI] [PubMed] [Google Scholar]
  46. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol. 2007;178:235–241. doi: 10.4049/jimmunol.178.1.235. [DOI] [PubMed] [Google Scholar]
  47. Osman AE, Mubasher M, ElSheikh NE, AlHarthi H, Al Yami AS, Rajalingam R, Al-Dehaimi A, Middleton D, ElGhazali G. Characterization of human killer immunoglobulin-like receptors (KIRs) among healthy Saudis. Hum Immunol. 2014;75:536–540. doi: 10.1016/j.humimm.2014.02.023. [DOI] [PubMed] [Google Scholar]
  48. Ozturk OG, Polat G, Atik U. Diversity of killer cell immunoglobulin-like receptor genes in Southern Turkey. Mol Biol Rep. 2012;39:1989–1995. doi: 10.1007/s11033-011-0945-5. [DOI] [PubMed] [Google Scholar]
  49. Parham P. Influence of KIR diversity on human immunity. Adv Exp Med Biol. 2005;560:47–50. doi: 10.1007/0-387-24180-9_6. [DOI] [PubMed] [Google Scholar]
  50. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. 2013;13:133–144. doi: 10.1038/nri3370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pedroza LS, Sauma MF, Vasconcelos JM, Takeshita LY, Ribeiro-Rodrigues EM, Sastre D, Barbosa CM, Chies JA, Veit TD, Lima CP, Oliveira LF, Henderson BL, Castro AP, Maia MH, Barbosa FB, Santos SE, Guerreiro JF, Sena L, Santos EJ. Systemic lupus erythematosus: association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus. 2011;20:265–273. doi: 10.1177/0961203310385266. [DOI] [PubMed] [Google Scholar]
  52. Petraglia MD. The Lower Paleolithic of the Arabian Peninsula: Occupations, adaptations, and dispersals. Journal of World Prehistory. 2003;17:141–179. [Google Scholar]
  53. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med. 2005;201:1025–1029. doi: 10.1084/jem.20050499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rayes R, Bazarbachi A, Khazen G, Sabbagh A, Zaatari G, Mahfouz R. Natural killer cell immunoglobulin-like receptors (KIR) genotypes in two arab populations: will KIR become a genetic landmark between nations? Mol Biol Rep. 2008;35:225–229. doi: 10.1007/s11033-007-9074-6. [DOI] [PubMed] [Google Scholar]
  55. Rosa A, Brehem A. African human mtDNA phylogeography at-a-glance. J Anthropol Sci. 2011;89:25–58. doi: 10.4436/jass.89006. [DOI] [PubMed] [Google Scholar]
  56. Soares P, Alshamali F, Pereira JB, Fernandes V, Silva NM, Afonso C, Costa MD, Musilova E, Macaulay V, Richards MB, Cerny V, Pereira L. The Expansion of mtDNA Haplogroup L3 within and out of Africa. Mol Biol Evol. 2012;29:915–927. doi: 10.1093/molbev/msr245. [DOI] [PubMed] [Google Scholar]
  57. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, Gauthier L, Romagne F, Ferracci G, Arosa FA, Moretta A, Sun PD, Ugolini S, Vivier E. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102:13224–13229. doi: 10.1073/pnas.0503594102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Tajik N, Shahsavar F, Mousavi T, Radjabzadeh MF. Distribution of KIR genes in the Iranian population. Tissue Antigens. 2009;74:22–31. doi: 10.1111/j.1399-0039.2009.01263.x. [DOI] [PubMed] [Google Scholar]
  59. Tajik N, Shahsavar F, Nasiri M, Radjabzadeh MF. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay. Int J Immunogenet. 2010;37:159–168. doi: 10.1111/j.1744-313X.2010.00906.x. [DOI] [PubMed] [Google Scholar]
  60. Torkar M, Norgate Z, Colonna M, Trowsdale J, Wilson MJ. Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex. Eur J Immunol. 1998;28:3959–3967. doi: 10.1002/(SICI)1521-4141(199812)28:12<3959::AID-IMMU3959>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  61. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics. 2002;54:221–229. doi: 10.1007/s00251-002-0463-7. [DOI] [PubMed] [Google Scholar]
  62. Vilches C, Castano J, Gomez-Lozano N, Estefania E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens. 2007;70:415–422. doi: 10.1111/j.1399-0039.2007.00923.x. [DOI] [PubMed] [Google Scholar]
  63. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251. doi: 10.1146/annurev.immunol.20.092501.134942. [DOI] [PubMed] [Google Scholar]
  64. Wagtmann N, Rojo S, Eichler E, Mohrenweiser H, Long EO. A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Curr Biol. 1997;7:615–618. doi: 10.1016/s0960-9822(06)00263-6. [DOI] [PubMed] [Google Scholar]
  65. Williams F, Middleton D, Leheny W. HLA-A and -B alleles, Cytokine polymorphisms and KIR gene frequencies in a population from Oman. Hum Immunol. 2004;65:1034–1038. [Google Scholar]
  66. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, Beck S, Trowsdale J. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000;97:4778–4783. doi: 10.1073/pnas.080588597. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Genetics and Molecular Biology are provided here courtesy of Sociedade Brasileira de Genética

RESOURCES